Market Research Logo

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

The global market for AD therapeutics and diagnostics by region should reach over $6.2 billion by 2020 from $4.4 billion in 2015, at a compound annual growth rate (CAGR) of 7.1% from 2015 to 2020.

This report provides:
An overview of the global market for Alzheimer's disease therapeutic and diagnostic technologies
Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
Review of programs in development and quantification of market opportunities
Discussion of the market segments' economic environment, technological descriptions and issues, and applications
Projections of usage in the major primary and secondary disease application areas
Profiles of major players in the industry


SCOPE OF THE STUDY

The scope of this study encompasses the global and regional markets for Alzheimer’s therapeutics and diagnostics. These markets are segmented by branded and generic drugs, mechanism of action, such as acetylcholine inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, a combination drug of donepezil and memantine, tau aggregation inhibitors (TAI) and amyloid-beta (Aβ) vaccines. Drugs are also segmented by the stage of Alzheimer’s disease they treat: mild to moderate, severe and prodromal.

BCC Research analyzed each market and its applications, regulatory environment, assistive technologies, market projections and market share. Issues discussed include the major drug profiles, clinical groundwork, technological features and trends. The regional markets for AD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Italy, Spain, Japan, China and India. These markets are grouped as North America, Europe and Asia-Pacific. The rest of the world markets are not addressed because of their economic insignificance with respect to this report.

CHAPTER 1 INTRODUCTION
STUDY OBJECTIVES
REASONS FOR DOING THE STUDY
INTENDED AUDIENCE
SCOPE OF THE STUDY
INFORMATION SOURCES
METHODOLOGY
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 SUMMARY
SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS)
SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2014-2020 ($ MILLIONS)
CHAPTER 3 OVERVIEW
ALZHEIMER'S DISEASE: DEFINITION AND MARKET STRUCTURE
FIGURE 1 CHANGE IN ALZHEIMER'S POPULATION AND COST OF CARE IN THE U.S., 2015-2030 (MILLIONS/$ BILLIONS)
ALZHEIMER'S DISEASE PATHOPHYSIOLOGY
AD AND AMYLOID CASCADE
AD AND TAUOPATHY
AD AND NEUROTRANSMITTER SYSTEMS
ALZHEIMER'S DISEASE ETIOLOGY
GENETIC FACTORS
Early-Onset Familial AD
Late-Onset Sporadic AD
NON-GENETIC FACTORS
ALZHEIMER'S DISEASE EPIDEMIOLOGY
AGE OF ONSET
INCIDENCE, PREVALENCE AND MORTALITY
Incidence of AD
Prevalence of AD
TABLE 1 PREVALENCE RATES OF ALZHEIMER'S BY REGION, 2014 (%)
FIGURE 2 GLOBAL PREVALENCE RATES OF ALZHEIMER'S BY AGE GROUP AND REGION (%)
TABLE 2 GLOBAL ALZHEIMER'S POPULATION BY AGE GROUP AND REGION, 2014 (MILLIONS)
FIGURE 3 GLOBAL ALZHEIMER'S POPULATION BY AGE GROUP AND REGION, 2014 (MILLIONS)
Mortality in AD
STAGES AND SEVERITY OF AD
Stage 1: Asymptomatic AD
Stage 2: Very mild AD
Stage 3: Mild AD
Stage 4: Moderate AD
Stage 5: Moderately severe AD
Stage 6: Severe decline
Stage 7: Very severe AD
COMORBIDITIES
TABLE 3 PHARMACOLOGICAL TREATMENT OF BPSD OF ALZHEIMER'S
DIAGNOSIS AND TREATMENT OF ALZHEIMER'S
DIAGNOSIS OF ALZHEIMER'S
Cognitive Status Testing
ADAS-Cog
Computerized Screening Tests
TABLE 4 COMPUTERIZED SCREENING TESTS USED IN DETECTING COGNITIVE
IMPAIRMENT
Genetic Testing
Brain Imaging
TABLE 5 BRAIN IMAGING TECHNOLOGIES AND APPLICATION IN THE ALZHEIMER'S
CONTEXT
Lumbar Puncture
PHARMACEUTICAL TREATMENT OF AD
CHAPTER 4 REGULATORY LANDSCAPE
U.S. FOOD AND DRUG ADMINISTRATION
TABLE 6 DIAGNOSTIC IMAGING TRACERS APPROVED BY THE FDA
EUROPEAN MEDICINES AGENCY
CHAPTER 5 GLOBAL MARKETS
INTRODUCTION
MARKET DYNAMICS
TOP PLAYERS IN THE GLOBAL MARKET FOR AD THERAPEUTICS
TABLE 7 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ALZHEIMER'S THERAPEUTICS, 2020 (%)
FIGURE 4 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ALZHEIMER'S THERAPEUTICS, 2020 (%)
GLOBAL MARKET FOR AD THERAPEUTICS AND DIAGNOSTICS
MARKET BY REGION
FIGURE 5 GLOBAL MARKET SHARES OF ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2015 (%)
TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 6 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2014-2020 ($ MILLIONS)
MARKET BY APPLICATION SEGMENT
TABLE 9 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 7 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION, 2014-2020 ($ MILLIONS)
Global Market for AD Therapeutics
Global Market for AD Therapeutics by Region
TABLE 10 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 8 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY REGION, 2014-2020 ($ MILLIONS)
Global Market for Branded/Generic AD Therapeutics
TABLE 11 GLOBAL MARKET FOR GENERIC/BRANDED ALZHEIMER'S THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
FIGURE 9 GLOBAL MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 ($ MILLIONS)
Global Market for AD Therapeutics by Mechanism of Action
TABLE 12 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 ($ MILLIONS)
FIGURE 10 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 ($ MILLIONS)
Global Market for AChEIs
TABLE 13 GLOBAL MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS)
FIGURE 11 GLOBAL MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 ($ MILLIONS)
TABLE 14 GLOBAL MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 12 GLOBAL MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY REGION, 2014-2020 ($ MILLIONS)
Global Market for NMDA Drugs
TABLE 15 GLOBAL MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 ($ MILLIONS)
FIGURE 13 GLOBAL MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 ($ MILLIONS)
TABLE 16 GLOBAL MARKET FOR NMDA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 14 GLOBAL MARKET FOR NMDA DRUGS BY REGION, 2014-2020 ($ MILLIONS)
Global Market for Other AD Therapeutics
TABLE 17 GLOBAL MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 15 GLOBAL MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY REGION, 2014-2020 ($ MILLIONS)
Global Market for AD Therapeutics by AD Stage
TABLE 18 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 ($ MILLIONS)
FIGURE 16 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 ($ MILLIONS)
Global Market for AD Diagnostics
Global AD Diagnostics Market by Region
TABLE 19 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 17 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY REGION, 2014-2020 ($ MILLIONS)
Global AD Diagnostics Market by Molecular Target
TABLE 20 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 ($ MILLIONS)
FIGURE 18 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 ($ MILLIONS)
CHAPTER 6 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS
NORTH AMERICAN MARKET
TABLE 21 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS)
FIGURE 19 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS)
NORTH AMERICAN MARKET FOR AD THERAPEUTICS BY COUNTRY
TABLE 22 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
FIGURE 20 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 ($ MILLIONS)
NORTH AMERICAN MARKET FOR BRANDED/GENERIC AD THERAPEUTICS
TABLE 23 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
FIGURE 21 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 ($ MILLIONS)
NORTH AMERICAN MARKET FOR AD THERAPEUTICS BY MECHANISM OF ACTION
TABLE 24 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 ($ MILLIONS)
FIGURE 22 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 ($ MILLIONS)
North American Market for AChEIs
TABLE 25 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS)
FIGURE 23 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 ($ MILLIONS)
TABLE 26 NORTH AMERICAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
FIGURE 24 NORTH AMERICAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS MARKET BY COUNTRY, 2014-2020 ($ MILLIONS)
North American Market for NMDA Drugs
TABLE 27 NORTH AMERICAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 ($ MILLIONS)
FIGURE 25 NORTH AMERICAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 ($ MILLIONS)
TABLE 28 NORTH AMERICAN MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
FIGURE 26 NORTH AMERICAN MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 ($ MILLIONS)
North American Market for Other AD Therapeutics
TABLE 29 NORTH AMERICAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
FIGURE 27 NORTH AMERICAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 ($ MILLIONS)
NORTH AMERICAN MARKET FOR AD THERAPEUTICS BY AD STAGE
TABLE 30 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 ($ MILLIONS)
FIGURE 28 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE 2014-2020 ($ MILLIONS)
NORTH AMERICAN MARKET FOR AD DIAGNOSTICS BY MOLECULAR TARGET
TABLE 31 NORTH AMERICAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 ($ MILLIONS)
FIGURE 29 NORTH AMERICAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 ($ MILLIONS)
CHAPTER 7 EUROPEAN MARKETS FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS
EUROPEAN MARKETS
TABLE 32 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS)
FIGURE 30 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS)
EUROPEAN MARKET FOR AD THERAPEUTICS BY COUNTRY
TABLE 33 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
FIGURE 31 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 ($ MILLIONS)
EUROPEAN MARKET FOR BRANDED/GENERIC AD THERAPEUTICS
TABLE 34 EUROPEAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
FIGURE 32 EUROPEAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 ($ MILLIONS)
EUROPEAN MARKET FOR AD THERAPEUTICS BY MECHANISM OF ACTION
TABLE 35 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 ($ MILLIONS)
FIGURE 33 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 ($ MILLIONS)
European Market for AChEIs
TABLE 36 EUROPEAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS)
FIGURE 34 EUROPEAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 ($ MILLIONS)
TABLE 37 EUROPEAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
FIGURE 35 EUROPEAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, 2014-2020 ($ MILLIONS)
European Market for NMDA Drugs
TABLE 38 EUROPEAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 ($ MILLIONS)
FIGURE 36 EUROPEAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 ($ MILLIONS)
TABLE 39 EUROPEAN MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
FIGURE 37 EUROPEAN MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 ($ MILLIONS)
European Markets for Other AD Therapeutics
TABLE 40 EUROPEAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
FIGURE 38 EUROPEAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
EUROPEAN MARKET FOR AD THERAPEUTICS BY AD STAGE
TABLE 41 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 ($ MILLIONS)
FIGURE 39 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 ($ MILLIONS)
EUROPEAN MARKET FOR AD DIAGNOSTICS
TABLE 42 EUROPEAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 ($ MILLIONS)
FIGURE 40 EUROPEAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 ($ MILLIONS)
CHAPTER 8 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS
ASIA-PACIFIC MARKET
TABLE 43 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS)
FIGURE 41 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS)
ASIA-PACIFIC MARKET FOR AD THERAPEUTICS BY REGION
TABLE 44 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
FIGURE 42 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
ASIA-PACIFIC MARKET FOR BRANDED/GENERIC AD THERAPEUTICS
TABLE 45 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
FIGURE 43 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 ($ MILLIONS)
ASIA-PACIFIC MARKET FOR AD THERAPEUTICS BY MECHANISM OF ACTION
TABLE 46 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 ($ MILLIONS)
FIGURE 44 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 ($ MILLIONS)
Asia-Pacific's Market for AChEIs
TABLE 47 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ACETYLCHOLIN-ESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS)
FIGURE 45 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ACETYLCHOLIN-ESTERASE INHIBITORS, 2014-2020 ($ MILLIONS)
TABLE 48 ASIA-PACIFIC MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
FIGURE 46 ASIA-PACIFIC MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, 2014-2020 ($ MILLIONS)
Asia-Pacific Market for NMDA Drugs
TABLE 49 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 ($ MILLIONS)
FIGURE 47 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 ($ MILLIONS)
TABLE 50 ASIA-PACIFIC MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
FIGURE 48 ASIA-PACIFIC MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 ($ MILLIONS)
ASIA-PACIFIC MARKET FOR AD THERAPEUTICS BY AD STAGE
TABLE 51 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 ($ MILLIONS)
FIGURE 49 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 ($ MILLIONS)
ASIA-PACIFIC MARKET FOR AD DIAGNOSTICS
TABLE 52 ASIA-PACIFIC MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 ($ MILLIONS)
FIGURE 50 ASIA-PACIFIC MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 ($ MILLIONS)
CHAPTER 9 PIPELINE ANALYSIS
AD PIPELINE LANDSCAPE
AD PIPELINE: CLINICAL STAGE
FIGURE 51 ALZHEIMER'S DRUGS IN THE PIPELINE BY DEVELOPMENT STAGE (NUMBER OF DRUGS)
AD PIPELINE: TREATMENT FOCUS
FIGURE 52 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)
AD PIPELINE BY DISEASE STAGE
FIGURE 53 LATE PHASE II/III ALZHEIMER'S DRUGS BY DISEASE STAGE (NUMBER OF DRUGS)
AD PIPELINE: MECHANISM OF ACTION
FIGURE 54 GLOBAL CLINICAL TRIALS ON ALZHEIMER'S DRUG BY MECHANISM OF ACTION (%)
TABLE 53 GLOBAL ALZHEIMER'S DRUGS IN THE PIPELINE BY MECHANISM OF ACTION
MAJOR AB-BASED THERAPIES IN CLINICAL TRIALS
BIIB037/ADUCANUMAB
Mode of Action
Clinical Trial Snapshot
Phase I Trials
Phase III Trials
ENGAGE and EMERGE
Safety
Efficacy
Administration
SOLANEZUMAB/LY2062430
Mode of Action
Clinical Trial Snapshot
Phase I Trial
Phase II Trials
Phase III Trials
EXPEDITION 1 and 2
Safety
Efficacy
Administration
RG1450/GANTENERUMAB
Mode of Action
Clinical Trial Snapshot
Phase I Trials
Phase II/III Trials
Efficacy
Administration
RG7412/CRENEZUMAB
Mode of Action
Clinical Trial Snapshot
Phase I Trials
Phase II Trials
Safety
Efficacy
Administration
MK-8931/VERUBECESTAT
Mode of Action
Clinical Trial Snapshot
Phase I Trials
Phase II Trials
Phase III Trials
Safety
Efficacy
Administration
Benchmarking
CAD106
Mode of Action
Clinical Trial Snapshot
Phase I Trial
Phase II Trials
Phase III Trials
Safety
Efficacy
Administration
MAJOR TAU-BASED THERAPIES IN CLINICAL TRIALS
LMTX
Mode of Action
Clinical Trial Snapshot
Phase I and II Trials
Phase III Trials
Safety
Efficacy
Administration
CHAPTER 10 COMPANION DIAGNOSTICS
INTRODUCTION
FIGURE 55 FDA-APPROVED CDX TECHNOLOGIES BY INDICATED THERAPEUTIC CLASS (%)
FIGURE 56 FDA-APPROVED CDX-DRUG PAIRS BY MOLECULAR TARGET
COMPANION IMAGING DIAGNOSTICS FOR AD
FIGURE 57 ONGOING AB AND TAU PET IMAGING CLINICAL TRIALS (%)
FIGURE 58 AB AND TAU PET IMAGING TRIALS BY CLINICAL TRIAL PHASE (NUMBER
OF TRIALS)
CIDX TECHNOLOGIES FOR AMYLOID VISUALIZATION
Market
TABLE 54 CIDX-DRUG PAIRS IN CLINICAL TRIALS
Pipeline
NAV-4694
Comparative Analysis of AB Tracer Technologies
Diagnostic Efficacy
Safety
Diagnostic Utility
CIDX TECHNOLOGIES FOR TAU-NFT VISUALIZATION
AV-1451
THK-5351
RO6958948
Comparative Analysis of Tau Tracers in Development
Diagnostic Efficacy
Safety
Diagnostic Utility
CIDX TECHNOLOGIES: AB VERSUS TAU IMAGING TECHNOLOGIES
CONCLUDING REMARKS
CHAPTER 11 COMPANY PROFILES
AB SCIENCE
ABBVIE INC.
AC IMMUNE SA
ALLERGAN PLC
AFFIRIS AG
AMARANTUS BIOSCIENCE HOLDINGS
ANAVEX LIFE SCIENCES
ASTRAZENECA
AVID RADIOPHARMACEUTICALS
AXON NEUROSCIENCE
AXOVANT SCIENCES
BIOGEN
BOEHRINGER INGELHEIM
DAIICHI SANKYO CO
DIAGENIC
EISAI
ELI LILLY
F. HOFFMANN LA ROCHE AG
GE HEALTHCARE
H. LUNDBECK A/S
JANSSEN PHARMACEUTICALS
MERCK & CO
NAVIDEA BIOPHARMACEUTICALS
NEUROTRAX CORP.
NOVARTIS PHARMA SERVICES AG
ONO PHARMACEUTICAL CO.
OTSUKA PHARMACEUTICALS
PFIZER INC
PIRAMAL IMAGING GMBH
TAURX THERAPEUTICS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report